Somaxon Pharmaceuticals, Inc. is one of the leading specialty pharmaceutical companies focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area.

Last week, Somaxon disclosed that the Company has received a Complete Response Letter from the FDA in which the FDA has clearly stated that the New Drug Application for Silenor could not be approved in its present form. Hence Somaxon is seeking another way for potential approval of this NDA through focusing on alternatives that utilizes the clinical data that has been submitted to the FDA to date. Somaxon stated that they will provide with any updates regarding their discussion with the FDA about Silenor’s NDA.

Enzon Pharmaceuticals, Inc is one of the leading biopharmaceutical companies dedicated to the development, manufacturing, commercialization of important medicines for patients with cancer and other life-threatening conditions. Enzon also engages in contract manufacturing for several pharmaceutical companies to broaden the Company’s revenue base. The Company’s drug development programs utilize several cutting-edge approaches, including its industry-leading PEGylation technology platform used to create product candidates with benefits such as reduced dosing frequency and less toxicity.

As announced earlier, Enzon has entered into a definitive deal to sell its specialty pharmaceutical business to the sigma-tau Group for $300 million plus an additional amount of up to $27 million based on success milestones. As per the agreement the Company will also receive royalties of 5 to 10 percent on incremental net sales above a 2009 baseline amount from Enzon’s four marketed specialty pharmaceutical products (Oncaspar, DepoCyt, Abelcet and Adagen) through 2014. The Company expects to close the deal shortly after this special meeting.

This recommendation is based on an analysis of one year data for all patients enrolled in the study for the period of 12 months and also includes both an assessment of safety and efficacy parameters. Based on this interim analysis, DMC is of the opinion that there are no major or unexpected safety concerns and recommends proceeding with the studies to test the efficacy and safety profile of oral calcitonin at two years as planned.

Allos Therapeutics, Inc. is one of the leading biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. FOLOTYN is the first and only drug approved in the U.S. for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. Allos is also exploring the potential of FOLOTYN in other indications. Additionally, the data demonstrated that promising results were observed in patients who responded to treatment with FOLOTYN and proceeded to receive SCT as initial subsequent therapy. Of the 109 patients evaluable for response, 6 proceeded to SCT after responding to FOLOTYN. Thus, responses to FOLOTYN permitted patients to proceed to a potential curative transplant option. This analysis also underscores the important role FOLOTYN for PTCL patients who have failed to respond to prior therapies, progressed after prior autologous stem cell transplant and as a bridge to stem cell transplant for patients who respond to FOLOTYN therapy.

Enzo Biochem have already presented their EGS21 clinical studies data recently at the Liver Conference where they showed that the oral administration of EGS21 is safe and appears to be biologically active in patients with insulin resistance and NASH (non-alcoholic steatohepatitis). Mr. Goldberg stated that this is a welcome recognition by a leading industry information organization and they are pleased to see a positive response. He also mentioned that EGS21 is a formulation derived from Enzo’s pioneering therapeutic platform that utilizes oral immune regulation for immune mediated diseases. Further he said that Enzo Therapeutics subsidiary has always viewed oral immune regulation as an exciting and promising platform and therefore they have continued to pursue through studies involving treatment candidates for unmet medical needs.

CEO of Origin Agritech, Liang Yuan commented that this state of the art drying facility will support increasing demands and quality for their premium seed products throughout China. This facility would also help them to improve the quality of their products and minimize inventory risks that would help them to grow as a company in the future. He further stated that this new seed drying facility only adds to the Origin’s vertically integrated infrastructure throughout all of mainland China.

From a location point of view the site of this facility is important from strategic perspective, as it lies in Gansu region which yields the highest seed production levels of seed corn in entire China. This new facility will also help Origin Agritech to prevent loss of seed stock which did not dry using conventional measures as surrounding environmental temperatures vary.

PolyMedix Inc is one of the leading and emerging biotechnology company focused on addressing large market opportunities relating to the development of novel drugs and biomaterials for the treatment of infectious diseases and acute cardiovascular disorders. PolyMedix is mainly dedicated to research in product areas involving fast and inexpensive trials, straightforward endpoints and early clinical proof of concept. PolyMedix’s compounds are based on biomimetics: non-peptide small molecule drug candidates that mimic the activity of proteins.

A registration statement relating to the offering was declared effective by the Securities and Exchange Commission on November 10, 2009, and the public offering is being made by means of a prospectus.

IntriCon’s CEO and President, Mark Gorder mentioned that they are really excited to unveil this new CDM device and it will be great news for cardiac diagnostic OEMs and their patients. He further stated that they have leveraged Datrix’s cardiac monitoring capabilities and IntriCon’s marketing abilities to develop a new wireless cardiac monitoring device that provides more patient comfort and ability to identify asymptomatic cardiac events which includes atrial fibrillation, brady arrhythmia, tachy arrhythmia and cardiac pause. This new CDM device will provide IntriCon the access to the emerging biotelemetry space.

Enzon Pharmaceuticals will file with the Securities and Exchange Commission a current report on Form 8-K which will also include the purchase agreement. Sigma-Tau Group is a global research and development pharmaceutical company that looks after the development and commercialization of medicines for rare diseases. This agreement will help Sigma-Tau to expand their current presence in the United States and also come out with new therapeutics which will help them expand their product portfolio. After the sale of these assets, Enzon Pharmaceuticals’ business will consists of its royalties which is Peg SN38 and other PEG and LNA technology platforms. Sigma-Tau Group has said that they will continue Enzon’s excellent work, especially in the field of rare diseases which is particularly stimulating one.

Entest Biomedical Inc is a majority owned subsidiary of Bio-Matrix Scientific Group Inc. Currently, the Company is into the development of stem cell therapy treatments for Chronic Obstructive Pulmonary Disease (COPD), testing procedures for diabetes, immuno-therapies for cancer, stem cell research applications for other illnesses and diabetes. The Company also is involved with medical device development (including stem cell extraction instrumentation). Entest is also seeking grant funding in excess of $3 million to support its research and is applying for government development contracts. And over the next five years, Entest Biomedical has decided that they will spend US$170 billion for the treatment of COPD in the United States.

COPD is the 4th leading cause of death in the United States and is projected that in next ten years it will be the 3rd leading cause of death in the United States. It is also estimated that more than US$800 billion will be spent on the medical related costs to combat chronic obstructive pulmonary disease. David Koos also stated that they might soon come up with a photoceutical device to direct stem cells to targeted damaged lung tissue which may actually reverse the impact and effects of COPD.